Cargando…
Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Haleema Shakur, Ian Roberts, et al.
Autor principal: | Simmon, Vincent F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797007/ https://www.ncbi.nlm.nih.gov/pubmed/19958522 http://dx.doi.org/10.1186/1745-6215-10-110 |
Ejemplares similares
-
The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
por: Shakur, Haleema, et al.
Publicado: (2009) -
Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply
por: Roberts, Ian, et al.
Publicado: (2009) -
Statistical analysis plan for the Erythropoietin in Traumatic Brain Injury trial: a randomised controlled trial of erythropoietin versus placebo in moderate and severe traumatic brain injury
por: Presneill, Jeffrey, et al.
Publicado: (2014) -
Risperidone versus placebo for aggression following traumatic brain injury: a feasibility randomised controlled trial
por: Deb, Shoumitro, et al.
Publicado: (2020) -
Interleukin-1 Receptor Antagonist as Therapy for Traumatic Brain Injury
por: Lindblad, Caroline, et al.
Publicado: (2023)